Rivaroxaban , a new oral factor Xa inhibitor , provides new data on anticoagulation
نویسندگان
چکیده
“Given the limitations with the vitamin K antagonists, there has been an ever-increasing need for the development of new an coagulant therapies.” Aurangzeb Siddique Haemostasis, Thrombosis & Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK Gregory YH Lip Haemostasis, Thrombosis & Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK Eduard Shantsila† †Author for correspondence: Haemostasis, Thrombosis & Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK Tel.: +44 121 507 5080 Fax: +44 121 554 4083 [email protected] Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation
منابع مشابه
Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011. The -xabans, as drugs from the group of oral direct factor Xa inhibitors are often referred to, comprise currently three drugs (apixaban, edoxaban, and rivaroxaban) w...
متن کاملDVT: A New Era in Anticoagulation Therapy Rivaroxaban: A New Oral Factor Xa Inhibitor
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation. It is selective for human factor Xa, for which it has 10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal inhibitory concentration [IC50], 20 mol/L). Rivaroxaban inhibits fa...
متن کاملNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and mortality resulting from cardioembolic stroke. Oral anticoagulation therapy has been shown to decrease the incidence of cardioembolic stroke in patients with AF by more than 50%. Appropriate use of anticoagulation with vitamin K antagonists requires precise adherence and monitoring. A number of factors tha...
متن کاملManaging new oral anticoagulants in the perioperative and intensive care unit setting.
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include direct Factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. In elective surgery, discontinuing their use ...
متن کاملNovel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
BACKGROUND AND PURPOSE Thrombosis of cerebral veins and sinus (cerebral venous thrombosis) is a rare stroke pathogenesis. Pharmaceutical treatment is restricted to heparin and oral anticoagulation with vitamin K antagonists (VKAs). METHODS Between January 2012 and December 2013, we recorded data from our patients with cerebral venous thrombosis. The modified Rankin scale was used to assess cl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009